The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC).
 
Makoto Nishio
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Chugai Pharma; Elekta; Lilly; Nicholas Piramal; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); MSD; Novartis (Inst); Ono Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Toyoaki Hida
Honoraria - Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Kazuhiko Nakagawa
Honoraria - AstraZeneca; Chugai Pharma; MSD; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca; Chugai Pharma; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Hiroshi Sakai
Honoraria - Chugai Pharma; Lilly; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Naoyuki Nogami
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Shinji Atagi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Toshiaki Takahashi
Speakers' Bureau - Ono Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst)
 
Hiroshi Nokihara
Honoraria - Boehringer Ingelheim; Lilly; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Hideo Saka
No Relationships to Disclose
 
Mitsuhiro Takenoyama
Speakers' Bureau - Chugai Pharma; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Shiro Fujita
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst)
 
Hiroshi Tanaka
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst)
 
Koji Takeda
Honoraria - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; Mochida Pharmaceutical Co. Ltd.; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst)
 
Miyako Satouchi
Speakers' Bureau - AstraZeneca; Chugai Pharma; Lilly; Nippon Boehringer Ingelheim; Novartis; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Hiroshi Isobe
Research Funding - Ono Pharmaceutical (Inst)
 
Makoto Maemondo
Consulting or Advisory Role - AstraZeneca Spain
Speakers' Bureau - AstraZeneca; Chugai Pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Koichi Goto
Honoraria - AstraZeneca; Boston Biomedical; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; GlaxoSmithKline
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Chugai Pharma (Inst); GlaxoSmithKline (Inst); MSD (Inst); Ono Pharmaceutical (Inst); OxOnc (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)
 
Tomonori Hirashima
No Relationships to Disclose
 
Koichi Minato
Research Funding - Ono Pharmaceutical (Inst)
 
Tomohide Tamura
Honoraria - Astellas Pharma; Boston Biomedical; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Novartis; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical